Residents in Massachusetts and New Hampshire can now participate in the pivotal Phase 3 trial testing the COVID-19 vaccine developed at Oxford University and now sponsored by AstraZeneca, known as AZD1222. Conducted by ActivMed Practices & Research LLC, the trial site research organization’s Michael J. McCartney, MD, leads as Principal Investigator overseeing the study in the firm’s Portsmouth, NH, facility. A solid research site in operation since 1994, founder Terri Stubbs participates as a volunteer in the development of an important new trial site accreditation standard.
The Vaccine Candidate
Now, New Hampshire residents can participate in the extensive investigation into the vaccine developed out of Oxford. Originally known as ChAdOx1 nCoV-19, the investigational product is derived from a virus (ChAdOx1), which actually is a weakened version of the cold virus called adenovirus that’s known to cause infections in chimpanzees. Teams in the Jenner Institute at the University of Oxford designed the vaccine candidate by adding genetic material associated with the SARS-CoV-2 virus known as Spike glycoprotein (S) to the base ChAdOx1.
Back in April, AstraZeneca and Oxford announced the agreement for the global development and distribution of the potential recombinant adenovirus vaccines targeting COVID-19.
There was a safety incident in the UK involving at least one individual and a neurological-based response, however, the trial resumed after regulators, including the U.S. Food and Drug Administration (FDA) deemed the vaccine safe.
The Trial Site
Based in Methuen, MA, with multiple locations in both Massachusetts and New Hampshire, ActivMed Practices & Research LLC brings major clinical trials to this part of New England. One of the leading COVID-19 vaccine candidates, the AstraZeneca-sponsored effort, represents a major opportunity for a successful vaccine candidate, and the residents of this part of America play a key role in advancing the battle against COVID-19.
Principal Investigator Dr. Michael McCartney shared recently in the local media Carriage Town News, “Our team at ActivMed looks forward to helping bring a vaccine against COVID-19 and a hopeful end to the pandemic.” The doctor continued, “We hope you will help, as we are looking for trial participants. We are trying to provide as safe an environment as possible. We are following CDC recommendations for participant safety. It is through this collaboration that we will be able to conduct this monumental endeavor. Looking forward to seeing you in our Portsmouth, NH, site.”
Owned and operated by Terri Stubbs since 1994, ActivMed has conducted over 800 clinical trials. They are a multi-specialty independent clinical research site with four (4) locations in northern Massachusetts and southern New Hampshire. The trial site organization focuses on a number of therapeutic areas, including Neurology, Family Medicine, Psychiatry, Dermatology, Gastroenterology, Pain and more. They also position that they embrace Virtual Trials.
Awards & Accreditation Activity
ActivMed Practices & Research LLC gets noted in TrialSite’s SiteWatch Leading category. The trial site organization has won a number of awards such as the CorproateLiveWire Innovation & Excellence Awards, 2019 & 2018 Top 25 Places to Work, North of Boston, 2014 Business of the Year and several others.
ActivMed has also been an early stage participant working toward site-level accreditation in association with the Site Accreditation and Standards Institute (SASI), a trial site accreditation initiative originally incubated out of the Alliance for Clinical Research Excellence and Safety.
In fact, founder Terri Stubbs has volunteered early on to help develop the trial site accreditation effort, volunteering with SASI as a domain leader for personnel and training. She is part of an international movement to ensure excellence and safety worldwide for research sites, benefiting patients and sponsors.
Call to Action: For those residents in and around Portsmouth, NH, or even northern MA, consider checking out the website for the COVID-19 vaccine study.